Drugs / BSI-082
last change Jan 2026 re-read 2 minutes ago

BSI-082

Developed for
metastatic malignant neoplasm
Investigated by
Biosin USA, Inc. · Lei Zheng

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07086768 Jan 2026 → Aug 2027 expected metastatic malignant neoplasm Lei Zheng Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BSI-082 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07086768
Route Intravenous “as an IV infusion” NCT07086768